Botulinum Toxin Type A Attenuates Activation of Glial Cells in Rat Medullary Dorsal Horn with CFA-induced Inflammatory Pain |
Kim, Min-Ji
(Department of Oral Physiology, School of Dentistry, Kyungpook National University)
Cho, Jin-Ho (Department of Oral Physiology, School of Dentistry, Kyungpook National University) Kim, Hye-Jin (Department of Oral Physiology, School of Dentistry, Kyungpook National University) Yang, Kui-Ye (Department of Oral Physiology, School of Dentistry, Kyungpook National University) Ju, Jin-Sook (Department of Oral Physiology, School of Dentistry, Kyungpook National University) Lee, Min-Kyung (Department of Dental Hygiene, Dong-Eui University) Park, Min-Kyoung (Department of Dental Hygiene, Kyung-Woon University) Ahn, Dong-Kuk (Department of Oral Physiology, School of Dentistry, Kyungpook National University) |
1 | Ahnert-Hilger G, Bigalke H. Molecular aspects of tetanus and botulinum neurotoxin poisoning. Prog Neurobiol. 1995;46:83-96. DOI |
2 | Traba Lopez A, Esteban A. Botulinum toxin in motor disorders: practical considerations with emphasis on interventional neurophysiology. Neurophysiol Clin. 2001; 31:220-229. DOI |
3 | Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol. 2004;251:I1-7. |
4 | Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache. 2000;40:300-305. DOI |
5 | Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001;56:1290-1293. DOI |
6 | Sheean G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep. 2002;6:460-469. DOI |
7 | Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000;40: 445-450. DOI |
8 | Smuts JA, Schultz D, Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache 2004;44:801-805. DOI |
9 | Gobel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001;91:195-199. DOI |
10 | Kitamura Y, Matsuka Y, Spigelman I, Ishihara Y, Yamamoto Y, Sonoyama W, Kamioka H, Yamashiro T, Kuboki T, Oguma K. Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience. 2009;159:1422-1429. doi: 10.1016/j.neuroscience.2009.01.066. DOI |
11 | Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35-42. DOI |
12 | Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007;120:2864-2874. DOI |
13 | Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006;122:315-325. DOI |
14 | Borodic GE, Acquadro MA. The use of botulinum toxin for the treatment of chronic facial pain. J Pain. 2002;3:21-27. DOI |
15 | Guo W, Wang H, Watanabe M, Shimizu K, Zou S, LaGraize SC, Wei F, Dubner R, Ren K. Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J Neurosci. 2007;27:6006-6018. DOI |
16 | Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nat Med. 2010;16:1267-1276. DOI |
17 | Xie YF, Zhang S, Chiang CY, Hu JW, Dostrovsky JO, Sessle BJ. Involvement of glia in central sensitization in trigeminal subnucleus caudalis (medullary dorsal horn). Brain Behav Immun. 2007;21:634-641. DOI |
18 | Lee S, Zhao YQ, Ribeiro-da-Silva A, Zhang J. Distinctive response of CNS glial cells in oro-facial pain associated with injury, infection and inflammation. Mol Pain. 2010;6:79. doi:10.1186/1744-8069-6-79. DOI |
19 | Zhuang ZY, Wen YR, Zhang DR, Borsello T, Bonny C, Strichartz GR, Decosterd I, Ji RR. A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci. 2006;26:3551-3560. DOI |
20 | Dieb W, Hafidi A. Astrocytes are involved in trigeminal dynamic mechanical allodynia: potential role of D-serine. J Dent Res. 2013;92:808-813. doi: 10.1177/0022034513498898. DOI |
21 | Lindia JA, McGowan E, Jochnowitz N, Abbadie C. Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J Pain. 2005;6:434-438. DOI |
22 | Raghavendra V, Tanga FY, DeLeo JA. Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci. 2004;20:467-473. DOI |
23 | Hua Y, Scheller RH. Three SNARE complexes cooperate to mediate membrane fusion. Proc Natl Acad Sci U S A. 2001;98:8065-8070. DOI |
24 | Sudhof TC. The synaptic vesicle cycle revisited. Neuron. 2000;28:317-320. DOI |
25 | Keller JE, Neale EA. The role of the synaptic protein snap-25 in the potency of botulinum neurotoxin type A. J Biol Chem. 2001;276:13476-13482. DOI |
26 | Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000;80:717-766. DOI |
27 | Lee WH, Shin TJ, Kim HJ, Lee JK, Suh HW, Lee SC, Seo K. Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced nociceptive responses in mice. Anesth Analg. 2011;112:228-235. doi: 10.1213/ANE.0b013e3181ffa1d7. DOI |
28 | Bach-Rojecky L, Lackovic Z. Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. Croat Med J. 2005;46:201-208. |
29 | Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalininduced pain. Pain. 2004;107:125-133. DOI |
30 | Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38:245-258. DOI |
31 | Luvisetto S, Marinelli S, Lucchetti F, Marchi F, Cobianchi S, Rossetto O, Montecucco C, Pavone F. Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain Res. 2006;1082:124-131. DOI |
32 | Bach-Rojecky L, Salkovic-Petrisic M, Lackovic Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol. 2010;633:10-14. doi: 10.1016/j.ejphar.2010.01.020. DOI |
33 | Bach-Rojecky L, Lackovic Z. Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav. 2009;94:234-238. doi: 10.1016/j.pbb.2009.08.012. DOI |
34 | Lee GW. Peripheral and central administration of botulinium toxin type A attenuated orofacial pain in rats. Thesis for master degree, 2013. |
35 | Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav. 1976;17:1031-1036. DOI |
36 | Ahn DK, Kim YS, Park JS. Central NO is involved in the antinociceptive action of intracisternal antidepressants in freely moving rats. Neurosci Lett. 1998;243:105-108. DOI |
37 | Ahn DK, Chae JM, Choi HS, Kyung HM, Kwon OW, Park HS, Youn DH, Bae YC. Central cyclooxygenase inhibitors reduced IL-1beta-induced hyperalgesia in temporomandibular joint of freely moving rats. Pain. 2005;117:204-213 DOI |
38 | Wang XM, Zhang ZJ, Bains R, Mokha SS. Effect of antisense knock-down of alpha(2a)-and alpha(2c)-adrenoceptors on the antinociceptive action of clonidine on trigeminal nociception in the rat. Pain. 2002;98:27-35. DOI |
39 | Park MK, Song HC, Yang KY, Ju JS, Ahn DK. Participation of peripheral P2X receptors in orofacial inflammatory nociception in rats. Int J Oral Biol. 2011;36:143-148. |
40 | Han SR, Yeo SP, Lee MK, Bae YC, Ahn DK. Early dexamethasone relieves trigeminal neuropathic pain. J Dent Res. 2010;89:915-920. doi: 10.1177/0022034510374056. DOI |
41 | Park CK, Kim K, Jung SJ, Kim MJ, Ahn DK, Hong SD, Kim JS, Oh SB. Molecular mechanism for local anesthetic action of eugenol in the rat trigeminal system. Pain. 2009;144:84-94. DOI |
42 | Rizo J, Sudhof TC. Mechanics of membrane fusion. Nat Struct Biol. 1998;5:839-842. DOI |
43 | Kim HJ, Lee GW, Kim MJ, Yang KY, Kim ST, Bae YC, Ahn DK. Antinociceptive effects of transcytosed botulinum neurotoxin type A on trigeminal nociception in rats. KJPP. 2015, in press. |
44 | Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6:521-532. |
45 | Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience. 2011;186:201-207. doi: 10.1016/j.neuroscience.2011.04.026. DOI |
46 | Marinelli S, Luvisetto S, Cobianchi S, Makuch W, Obara I, Mezzaroma E, Caruso M, Straface E, Przewlocka B, Pavone F. Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience. 2010;171:316-328. doi: 10.1016/j.neuroscience.2010.08.067. DOI |
47 | DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain. 2001;90:1-6. DOI |
48 | Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24:450-455. DOI |
49 | Wieseler-Frank J, Maier SF, Watkins LR. Glial activation and pathological pain. Neurochem Int. 2004;45:389-395. DOI |
50 | Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19:312-318. DOI |
51 | Inoue K, Tsuda M. Purinergic systems, neuropathic pain and the role of microglia. Exp Neurol. 2012;234:293-301. doi: 10.1016/j.expneurol.2011.09.016. DOI |
52 | Tsuda M, Tozaki-Saitoh H, Inoue K. Purinergic system, microglia and neuropathic pain. Curr Opin Pharmacol. 2012;12:74-79. doi: 10.1016/j.coph.2011.10.014. DOI |
53 | Garrison CJ, Dougherty PM, Kajander KC, Carlton SM. Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res. 1991;565:1-7. DOI |
54 | Didier M, Harandi M, Aguera M, Bancel B, Tardy M, Fages C, Calas A, Stagaard M, Mollgard K, Belin MF. Differential immunocytochemical staining for glial fibrillary acidic (GFA) protein, S-100 protein and glutamine synthetase in the rat subcommissural organ, nonspecialized ventricular ependyma and adjacent neuropil. Cell Tissue Res. 1986;245:343-351. |
55 | Sweitzer SM, Colburn RW, Rutkowski M, DeLeo JA. Acute peripheral inflammation induces moderate glial activation and spinal IL-1beta expression that correlates with pain behavior in the rat. Brain Res. 1999;829:209-221. DOI |
56 | Colburn RW, Rickman AJ, DeLeo JA. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp Neurol. 1999;157:289-304. DOI |